Semaglutide vs Tirzepatide: Which GLP-1 Is Better?

Semaglutide and tirzepatide are the two active ingredients dominating the GLP-1 medication landscape. Semaglutide powers Wegovy (weight loss), Ozempic (diabetes), and Rybelsus (oral diabetes). Tirzepatide powers Zepbound (weight loss) and Mounjaro (diabetes). Together, they account for the vast majority of GLP-1 prescriptions written in the United States.

But they are not the same drug. They work through different mechanisms, produce different results in clinical trials, have different side effect profiles, and come in different formulations at different prices. If you're starting a GLP-1 program — or considering switching — this comparison breaks down everything you need to know about these two molecules based on published trial data and the current April 2026 landscape.

We've already covered the brand-name comparison in our Wegovy vs Zepbound guide. This article goes deeper — comparing the active ingredients themselves across every product, indication, and clinical data point available.

How They Work: One Receptor vs Two

The fundamental difference between semaglutide and tirzepatide comes down to receptor targets. Understanding this helps explain why their clinical results differ.

Semaglutide is a GLP-1 receptor agonist. It mimics a single gut hormone — glucagon-like peptide-1 — that your body naturally releases after eating. By binding to GLP-1 receptors in the brain, gut, and pancreas, semaglutide suppresses appetite, slows gastric emptying (so you feel full longer), and improves blood sugar regulation. It was developed by Novo Nordisk and first approved by the FDA in 2017 (as Ozempic for Type 2 diabetes). The weight-loss version, Wegovy, was approved in June 2021.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — what researchers call a "twincretin." It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GIP is another incretin hormone involved in glucose metabolism, fat storage, and energy balance. By hitting two targets instead of one, tirzepatide engages additional metabolic pathways that semaglutide doesn't directly activate. It was developed by Eli Lilly and first approved in 2022 (as Mounjaro for Type 2 diabetes). Zepbound (the weight-loss brand) followed in November 2023.

Both drugs are peptide-based and engineered to last about a week in your body, allowing weekly dosing. Both were originally designed as diabetes treatments and later proven effective for weight management at higher doses. But from a pharmacology standpoint, tirzepatide is doing more — activating two hormonal systems while semaglutide activates one.

Weight Loss: What the Clinical Trials Show

The strongest evidence comes from each drug's Phase 3 clinical trial programs. For semaglutide, that's the STEP trials (Semaglutide Treatment Effect in People with Obesity). For tirzepatide, it's the SURMOUNT trials. Both studied patients without diabetes who had obesity or overweight with at least one weight-related comorbidity.

No large, published head-to-head trial has directly compared semaglutide and tirzepatide for weight loss in the same patient population. So we compare across their respective trials, with the caveat that populations, study designs, and durations differed slightly.

The numbers tell a clear story. Semaglutide at its maximum dose (2.4 mg) produces roughly 15% body weight loss. Tirzepatide at its low dose (5 mg) matches that, and at 10-15 mg it significantly exceeds it — reaching 20-21% average body weight loss at the highest dose. For a 250-pound patient, that's the difference between losing roughly 37 pounds on semaglutide and 52 pounds on high-dose tirzepatide.

Perhaps more telling is the proportion of patients hitting the 20% weight loss threshold. Only about a third of semaglutide patients reached that mark, while more than half of tirzepatide patients at 15 mg did. That's a substantial difference in the probability of achieving the kind of weight loss that resolves obesity-related conditions like sleep apnea, fatty liver disease, and Type 2 diabetes.

The SURMOUNT-5 trial (published 2024) did provide a direct head-to-head comparison in patients with obesity: tirzepatide 15 mg achieved 20.2% weight loss versus semaglutide 2.4 mg at 13.7% over 72 weeks — a statistically significant 47% greater relative weight reduction. This is the closest we have to a definitive comparison, and it confirms the cross-trial signals.

Beyond Weight Loss: Cardiovascular & Metabolic Benefits

Weight loss is the headline number, but these medications have broader metabolic effects that matter for long-term health. Here's where the two active ingredients stand on outcomes beyond the scale.

Semaglutide: Proven cardiovascular benefit. The SELECT trial (published in NEJM, 2023) was a landmark study of 17,604 adults with overweight or obesity and established cardiovascular disease — but without diabetes. Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE — heart attack, stroke, or cardiovascular death) by 20% compared to placebo over a median follow-up of 39.8 months. This led to an expanded FDA label for Wegovy in March 2024 specifically for cardiovascular risk reduction in adults with obesity.

This is a big deal. SELECT is one of the first trials to show that a weight-loss medication reduces hard cardiovascular endpoints independent of diabetes. It gives semaglutide a proven benefit that goes beyond weight loss — and gives insurers a reason to cover Wegovy even under plans that exclude weight-loss drugs.

Tirzepatide: Cardiovascular trial ongoing. The SURPASS-CVOT trial is Eli Lilly's cardiovascular outcomes study for tirzepatide. Results have been reported showing non-inferiority to the GLP-1 agonist dulaglutide for cardiovascular safety in patients with Type 2 diabetes, but a dedicated obesity CVOT comparable to SELECT has not yet been published. This means tirzepatide does not currently have an FDA-approved cardiovascular indication for patients without diabetes. Lilly is running additional studies, but for now, semaglutide has the stronger cardiovascular evidence.

Diabetes outcomes. Both are powerhouse diabetes medications. In the SURPASS trials, tirzepatide reduced HbA1c by 1.87-2.07% (depending on dose) in patients with Type 2 diabetes, with some patients achieving HbA1c below 5.7% — essentially non-diabetic levels. Semaglutide in the SUSTAIN trials33647-2/fulltext) reduced HbA1c by about 1.5-1.8%. Tirzepatide's dual mechanism appears to give it an edge for blood sugar control as well.

Both medications improve blood pressure, lipid profiles, and markers of liver health. Tirzepatide tends to show slightly larger improvements in metabolic markers in cross-trial comparisons, consistent with its greater weight loss. But semaglutide is the only one with proven, published cardiovascular event reduction in a non-diabetic obesity population. For patients with existing heart disease, that's a meaningful differentiator.

Side Effects Compared

Both semaglutide and tirzepatide cause gastrointestinal side effects — primarily nausea, diarrhea, vomiting, and constipation. These are expected effects of GLP-1 receptor activation in the gut and brain. Side effects are most common during dose escalation and typically improve as your body adjusts. Here's what the clinical trial data from the Wegovy and Zepbound prescribing information shows:

Semaglutide has noticeably higher nausea and vomiting rates across the board. Roughly 44% of Wegovy patients experienced nausea versus 24-33% on Zepbound (dose-dependent). Vomiting rates are particularly different — 24% for semaglutide versus 6-13% for tirzepatide. This is clinically significant and may reflect differences in how each drug affects gastric motility.

However, context matters. The STEP and SURMOUNT trials used different dose escalation schedules and had somewhat different patient populations. Real-world tolerability depends on how quickly your provider ramps up the dose, whether you follow dietary guidelines (smaller meals, avoiding high-fat foods), and individual variation. Many patients on either drug find that side effects are manageable and largely confined to the first few weeks at each new dose level.

If you've struggled with GI side effects on semaglutide, switching to tirzepatide is worth discussing with your provider — the lower nausea and vomiting rates may mean better tolerability. Conversely, some patients tolerate semaglutide better than tirzepatide. Individual responses vary, and the only way to know for sure is to try under medical supervision.

FDA-Approved Forms & Dosing

Both active ingredients are available under multiple brand names for different indications. Here's the full landscape as of April 2026:

Semaglutide has more delivery options right now. The oral Wegovy tablet (approved December 2025) gives needle-averse patients a pill form for weight loss. Tirzepatide is currently injection-only for both Zepbound and Mounjaro, though Lilly has oral tirzepatide in late-stage clinical trials. Also note that Foundayo (orforglipron), listed above for reference, is a different molecule — a non-peptide oral GLP-1 agonist by Eli Lilly approved April 2026 — not tirzepatide in pill form.

From a dosing flexibility standpoint, tirzepatide has an edge. Zepbound and Mounjaro offer six dose levels (2.5 through 15 mg), giving providers more room to fine-tune the dose based on efficacy and side effects. Semaglutide's injectable form has a fixed maintenance dose of 2.4 mg for weight loss — you either tolerate it or you don't. That said, semaglutide's dose escalation is more gradual (five steps to max dose vs. tirzepatide's five to six steps), which some patients prefer.

Pricing: April 2026

Cost is often the deciding factor, especially for patients without insurance coverage. The pricing landscape has shifted significantly over the past year with manufacturer direct programs, Medicare changes, and announced price cuts. Here's where things stand:

For patients paying out of pocket, tirzepatide currently has the edge. Eli Lilly's LillyDirect program offers Zepbound vials starting at $299/month — the cheapest branded GLP-1 injectable option. Novo Nordisk's NovoCare program prices Wegovy at $349/month for self-pay patients. Both are dramatically lower than list prices, but still a significant monthly expense. Use our cost calculator to estimate what you'll actually pay based on your insurance situation.

For insured patients, both manufacturers offer savings cards that can bring copays as low as $25/month with eligible commercial insurance. Which drug your plan prefers varies — some insurers have exclusive deals with Novo Nordisk, others with Lilly. The most reliable strategy is to ask your provider to check coverage for both and go with whichever is on your formulary.

If you're uninsured or underinsured, compare your options carefully. Check our provider rankings to see which telehealth platforms offer each medication at the best price, including those with bundled visit fees.

Which One Should You Choose?

After reviewing all the data, here's our honest editorial take: tirzepatide is the stronger weight loss drug, and semaglutide is the better-proven cardiovascular drug. The right choice depends on what matters most for your specific situation.

Choose semaglutide (Wegovy/Ozempic) if:

• •You have established cardiovascular disease or significant heart risk factors — the SELECT trial data is a real, proven benefit that tirzepatide can't match yet
• •You want an oral option — Wegovy's pill form means no injections, which matters a lot for long-term adherence (see our oral vs injectable comparison)
• •Your insurance covers Wegovy but not Zepbound — coverage trumps clinical trial averages every time
• •You're already on Ozempic for diabetes and want to step up to the weight-loss dose — staying with the same molecule simplifies the transition
• •You want the longest safety track record — semaglutide has been on the market since 2017 and has more published long-term data

Choose tirzepatide (Zepbound/Mounjaro) if:

• •Maximizing weight loss is your primary goal — tirzepatide consistently produces 5-7 percentage points more weight loss across trials, and the SURMOUNT-5 head-to-head confirmed this advantage
• •You've struggled with GI side effects on semaglutide — tirzepatide's lower nausea and vomiting rates may make it more tolerable
• •You want more dosing flexibility — six dose levels let your provider fine-tune between efficacy and side effects
• •You have Type 2 diabetes and want the best blood sugar control — tirzepatide shows slightly larger HbA1c reductions
• •You're paying out of pocket — LillyDirect vials at $299/month are currently the cheapest branded option

The bottom line: If we had to pick one molecule on pure clinical performance, tirzepatide has the edge — more weight loss, better tolerability profile, stronger diabetes outcomes, and competitive pricing. But medicine isn't a one-size-fits-all game. Semaglutide's cardiovascular data, oral formulation, and upcoming price cuts make it the better choice for millions of patients. The best medication is the one you can access, afford, and tolerate long enough to see results.

Not sure which one fits your profile? Take our eligibility quiz to get personalized recommendations, or browse our provider rankings to find a telehealth platform that prescribes both options. For a broader overview of how these medications work, check out our beginner's guide to GLP-1 medications.

Sources

• •STEP 1 Trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity — Wilding et al., New England Journal of Medicine, 2021
• •SURMOUNT-1 Trial: Tirzepatide Once Weekly for the Treatment of Obesity — Jastreboff et al., New England Journal of Medicine, 2022
• •SURMOUNT-5 Trial: Tirzepatide vs Semaglutide for Obesity — Rodriguez et al., New England Journal of Medicine, 2024
• •SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — Lincoff et al., New England Journal of Medicine, 2023
• •SURPASS-1 Trial: Tirzepatide vs Placebo in Type 2 Diabetes — Rosenstock et al., New England Journal of Medicine, 2021
• •SUSTAIN-6 Trial: Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes33647-2/fulltext) — Marso et al., The Lancet, 2017
• •Wegovy (semaglutide) Prescribing Information — FDA/Novo Nordisk, updated 2025
• •Zepbound (tirzepatide) Prescribing Information — FDA/Eli Lilly, 2023
• •Medicare GLP-1 Bridge Program — Centers for Medicare & Medicaid Services, 2026